SCHEMBL17100591

SCHEMBL17100591

Cc1ccc(-c2noc(N3CCN(Cc4ccccc4C)CC3)n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.58
LMNA P02545 6/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
ALDH1A1 P00352 4/20 0.58
TSHR P16473 3/20 0.58
HSD17B10 Q99714 1/20 0.58
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
TP53 P04637 1/20 0.52
MAPK1 P28482 2/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
USP2 O75604 1/20 0.46
HTT P42858 1/20 0.46
KDM4E B2RXH2 1/20 0.46
CYP2A13 Q16696 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17115008 0.93 KMT2A (0.55) MAPTLMNASMN1; SMN2ALDH1A1TSHR
SCHEMBL17100772 0.91 MAPT (0.59) MAPTLMNASMN1; SMN2ALDH1A1TSHR
SCHEMBL17100671 0.84 MAPT (0.56) MAPTLMNAALDH1A1KMT2AMEN1
SCHEMBL17100616 0.83 LMNA (0.67) MAPTLMNASMN1; SMN2ALDH1A1TSHR
SCHEMBL17100630 0.80 SMN1; SMN2 (0.59) MAPTLMNASMN1; SMN2ALDH1A1TSHR
SCHEMBL17100762 0.80 CYP2D6 (0.57) MAPTLMNASMN1; SMN2ALDH1A1TSHR
SCHEMBL17100609 0.77 ALDH1A1 (0.54) MAPTLMNASMN1; SMN2ALDH1A1TSHR
SCHEMBL17100737 0.77 ALDH1A1 (0.55) MAPTLMNASMN1; SMN2ALDH1A1TSHR
SCHEMBL17100661 0.77 LMNA (0.55) MAPTLMNASMN1; SMN2ALDH1A1NPC1
SCHEMBL14488725 0.77 KMT2A (0.55) MAPTLMNASMN1; SMN2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US claimed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US claimed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP claimed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO claimed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT MAPT 3/4885LMNA 760/4885SMN1; SMN2 11/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT MAPT 3/4885LMNA 748/4885SMN1; SMN2 11/4885
US-20170073319-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT MAPT 3/4885LMNA 760/4885SMN1; SMN2 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.